Skip to main content
Premium Trial:

Request an Annual Quote

Ubiquitome, AsureQuality Collaborate on Food Safety Testing

NEW YORK (GenomeWeb) – Ubiquitome and AsureQuality have reached an agreement to try out mobile molecular testing in food safety and production.

Under the terms of the agreement announced today, AsureQuality will use Ubiquitome's hand-held, battery-powered Freedom4 real-time PCR device in its food quality assurance programs. Potential applications include animal disease control, pest management, and surveillance.

"We operate across a broad range of market sectors and we see a number of opportunities where the ability to deliver accurate, sensitive, and timely diagnostic information can add value to our customers," AsureQuality CEO John McKay said in a statement.

Ubiquitome CEO Paul Pickering added that the Freedom4, which was launched in September 2014, has applications in both food safety testing and pathogen identification.

Financial and other terms of the agreement were not disclosed.

New Zealand-based Ubiquitome is a spinout of the University of Otago. In December 2014, it announced plans to develop a mobile Ebola assay for the Freedom4.


The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.